Jennifer A Cochran

US Patent:

8329826, Dec 11, 2012

Filed:

Nov 5, 2009

Appl. No.:

12/590288

Inventors:

Laura Hartmann - Berlin, DE
Stayce E. Beck - Menlo Park CA, US
Jennifer R Cochran - Stanford CA, US
Curtis W Frank - Cupertino CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

C08F 8/14
C08F 8/32

US Classification:

5253299, 5253301, 525379, 525384

Abstract:

Surface modification methods for an interpenetrating polymer network (IPN) hydrogel to provide a basis for cell or tissue attachment are provided. The method involves the activation of functional groups on the surface of the IPN hydrogel. The activated functional groups are then reacted with amine-containing molecules or hydroxyl-containing molecules. The methods (i) can be performed in an aqueous environment and do not require the use of any organic solvent, (ii) do not require UV treatment, thereby avoiding denaturation of the IPN hydrogel or proteins, and/or (iii) can be performed as a one pot reaction.

US Patent:

8536301, Sep 17, 2013

Filed:

Apr 3, 2009

Appl. No.:

12/418376

Inventors:

Jennifer R. Cochran - Stanford CA, US
Richard Kimura - Stanford CA, US
Aron M. Levin - Menlo Park CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

A61K 38/04

US Classification:

530324

Abstract:

Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (αβ) or vitronectin (αβand αβintegrins) are disclosed. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e. g. , EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [(Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.

US Patent:

8618254, Dec 31, 2013

Filed:

Jul 20, 2012

Appl. No.:

13/554954

Inventors:

Amato J. Giaccia - Stanford CA, US
Erinn Bruno Rankin - Waltham MA, US
Jennifer R. Cochran - Stanford CA, US
Douglas Jones - Cambridge MA, US
Mihalis Kariolis - Stanford CA, US
Katherine Fuh - Palo Alto CA, US
Yu Miao - Sunnyvale CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

C07K 14/705
C07K 14/71
C07K 16/46
A61K 38/16

US Classification:

530350, 5303873, 514 11

Abstract:

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

US Patent:

20080249008, Oct 9, 2008

Filed:

Mar 20, 2007

Appl. No.:

11/725695

Inventors:

Jennifer R. Cochran - Stanford CA, US
K. Dane Wittrup - Chestnut Hill MA, US

International Classification:

A61K 38/18
C07K 14/485
A61P 35/00
A61P 25/00
A61K 48/00
C40B 30/04
C12P 21/00
A61P 9/00
A61P 17/02
C07H 21/00

US Classification:

514 12, 530324, 536 235, 514 44, 435 691, 506 9

Abstract:

The present invention is based, in part, on our discovery that EGF can be engineered to generate mutants that bind to the EGF receptor (EGFR) of a cell and that have a desirable effect on the activity of the cell. For example, the mutants can agonize the receptor (i.e., increase a biological activity of the receptor), or antagonize the receptor (i.e., decrease or inhibit a biological activity of the receptor). In turn, the rate at which the cell proliferates, for example, can be changed. Moreover, some of these mutants bind EGFR with a higher affinity than wild-type EGF exhibits. The affinity may increase by about, for example, 2-, 5-, 10-, 15-, 20-, 25-, 30-, 50-, or 100-fold relative to wild-type EGF.

US Patent:

20090117166, May 7, 2009

Filed:

Aug 15, 2008

Appl. No.:

12/228884

Inventors:

David Myung - Santa Clara CA, US
Stayce Beck - Menlo Park CA, US
Jaan Noolandi - Mountain View CA, US
Christopher N. Ta - Saratoga CA, US
Jennifer R. Cochran - Stanford CA, US
Curtis W. Frank - Cupertino CA, US

International Classification:

A61F 2/04
A61K 9/10
A61K 38/39
A61K 38/30
A61K 38/18

US Classification:

424422, 424484, 514 12

Abstract:

A bio-mimetic or bio-implantable material based on a sequential process of coupling biomolecule layers to a polymer layer is provided. In general, the material could be based on two or more biomolecule layers starting with one of the layers covalently linked to the polymer layer via cross-linkers and the other layers sequentially and covalently linked using cross-linkers to the previously added layer. The polymer layer could be a hydrogel or an interpenetrating polymer network hydrogel. The first layer of biomolecules could be a collagen type, fibronectin, laminin, extracellular matrix protein, or any combinations thereof. The second layer of biomolecules typically is a growth factor, protein or stimulant. The cross-linkers are either water soluble or insoluble bifunctional cross-linkers or azide-active-ester crosslinkers. The material and process as taught in this invention are useful in the field of tissue engineering and wound healing.

US Patent:

20090280182, Nov 12, 2009

Filed:

Apr 29, 2009

Appl. No.:

12/387318

Inventors:

Stayce Beck - Menlo Park CA, US
David Myung - Santa Clara CA, US
Curtis W. Frank - Cupertino CA, US
Jennifer R. Cochran - Stanford CA, US
Michael T. Longaker - Atherton CA, US
George P. Yang - San Francisco CA, US
Daphne P. Ly - Palo Alto CA, US
Shira G. Mandel - Palo Alto CA, US

International Classification:

A61K 9/10
A61K 38/16

US Classification:

424486, 514 12

Abstract:

Interpenetrating network hydrogels are described that may be incorporated into wound dressings and/or in implants. The properties of the interpenetrating network hydrogel may be tuned to control an amount of moisture in a wound environment. The devices, methods, and kits described herein may be adapted to treat a variety of wound types at a variety of healing stages over a range of time scales. Some hydrogels may be configured to deliver one or more vulnerary agents to a wound. The interpenetrating network hydrogels may also be adapted to control a rate and/or amount of moisture uptake so that the hydrogels may be used as expandable implants to expand tissue.

US Patent:

20110136740, Jun 9, 2011

Filed:

Nov 2, 2010

Appl. No.:

12/938216

Inventors:

Jennifer R. Cochran - Stanford CA, US
Adam P. Silverman - Redwood City CA, US
Mihalis S. Kariolis - Stanford CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

A61K 38/16
C07K 14/00
C07K 1/14
A61P 7/02

US Classification:

514 138, 530321, 514 211, 530300

Abstract:

Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against αβintegrin, found on platelets, and a method of using the same in anti-thrombotic therapies. The present peptides utilize a cystine knot scaffold derived from modified agouti-related protein or agatoxin, An alternate library screening strategy was used to isolate variants of peptides that selectively bound to αβintegrin or to both αβand αβintegrins. Unique consensus sequences were identified within the identified peptides suggesting alternative molecular recognition events that dictate different integrin binding specificities. In addition, the engineered peptides prevented human platelet aggregation in a plasma-based assay and showed high binding affinity for αβintegrin.

US Patent:

20120020889, Jan 26, 2012

Filed:

Jan 18, 2010

Appl. No.:

13/145059

Inventors:

Jennifer R. Cochran - Stanford CA, US
Adam Silverman - Redwood City CA, US
Douglas Jones - Cambridge MA, US
Niv Papo - Palo Alto CA, US

International Classification:

A61K 49/00
A61K 38/18
C12N 15/62
C12N 5/071
A61P 17/06
C40B 30/04
A61P 35/00
A61P 27/02
A61P 19/02
C07K 19/00
G01N 33/574

US Classification:

424 91, 530399, 514 81, 536 234, 435375, 435 723, 506 9

Abstract:

Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.